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Background and Rationale: Among the key players in the pathogenesis of
Amyotrophic Lateral Sclerosis (ALS), microglia and T regulatory lymphocytes (Treg) are
candidate cells for modifying the course of the disease. The gut microbiota (GM) acts
by shaping immune tolerance and regulating the Treg number and suppressive function,
besides circulating neuropeptides, and other immune cells that play in concert through
the gut-brain axis. Previous mouse models have shown an altered enteric flora in
early stage ALS, pointing to a possible GM role in ALS pathogenesis. Fecal Microbial
Transplantation (FMT) is a well-known therapeutic intervention used to re-establish the
proper microenvironment and to modulate enteric and systemic immunity.
Methods: We are going to perform a multicenter randomized double-blind clinical trial
employing FMT as a therapeutic intervention for ALS patients (NCT0376632). Forty-two
ALS patients, at an early stage, will be enrolled with a 2:1 allocation ratio (28 FMT-treated
patients vs. 14 controls). Study duration will be 12 months per patient. Three endoscopic
procedures for intestinal biopsies in FMT and control groups are predicted at baseline,
month 6 andmonth 12; at baseline and at month 6 fresh feces from healthy donors will be
infused at patients in the intervention arm. The primary outcome is a significant change
in Treg number between FMT-treated patients and control arm from baseline to month
6. Secondary outcomes include specific biological aims, involving in-depth analysis of
immune cells and inflammatory status changes, central and peripheral biomarkers of
ALS, besides comprehensive analysis of the gut, saliva and fecal microbiota. Other
secondary aims include validated clinical outcomes of ALS (survival, forced vital capacity,
and modifications in ALSFRS-R), besides safety and quality of life.
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Expected Results: We await FMT to increase Treg number and suppressive
functionality, switching the immune system surrounding motorneurons to an anti-
inflammatory, neuroprotective status. Extensive analysis on immune cell populations,
cytokines levels, and microbiota (gut, fecal and saliva) will shed light on early processes
possibly leading the degenerative ALS course.
Conclusions: This is the first trial with FMT as a potential intervention to modify
immunological response to ALS and disease progression at an early stage.
Keywords: amyotrophic lateral sclerosis, microbiota, adaptive immunity, fecal microbiota transplantation, T cells,
treg lymphocytes, randomized controlled clinical trial
INTRODUCTION
When questioning why so many failures in clinical trials in
amyotrophic lateral sclerosis (ALS), the lack of a complete
comprehension of the pathogenic systems behind the disease
onset and progression might be accounted as one of the main
reasons. Indeed, ALS is a complex syndrome. Aberrant cellular
pathways convey from protein misfolding, with endoplasmic
reticulum stress, defective autophagy and damage to cytoskeleton
(1), associated to staggered RNA processing and mitochondria
homeostasis, increased oxidative stress, enhanced excitotoxicity,
reduced neurotrophic sustenance, and to a glial inflammatory
response that is oriented toward a harmful side (2).
Recent studies highlighted the role of microglia and opened
new perspectives in the knowledge of the non-cell autonomous
molecular mechanisms possibly contributing to ALS, launching
them as a plausible target for many clinical trials. During ALS
progression, activated microglia switch from the M2 phenotype,
which is neuroprotective and supports tissue repair and neuron
survival through the release of neuroprotective factors, to
M1 phenotype, which is toxic and contributes to neuronal
death through pro-inflammatory cytokines production, and
tissue destruction. Therapeutic approaches targeting microglia
polarization to induce theM2 phenotype are promising strategies
to contain local neurodegeneration and improve ALS outcome
(3). Indeed, in animal models of the disease, diminishing
the mutant levels of microglia sharply slowed later disease
progression (4).
M1/M2 macrophages phenotypes switch have been shown to
be induced by CD4+ T cells, especially CD4+CD25+Foxp3+ T
regulatory (Treg) cells (5, 6). In the blood and spinal cord of
patients with ALS, CD4+ T cells (T helper—Th) are increased,
especially with a predominantly pro-inflammatory Th1/Th17
phenotype (7). On the contrary, Tregs from blood of ALS patients
demonstrated a significant decrease in the ability to suppress
the proliferation of the effector T cells; and of note, the loss
extent in suppression was correlated with disease progression
(7). The passive transfer of mSOD1 Tregs into ALS mice lacking
functional T lymphocytes prolonged their survival while FoxP3
mRNA in the spinal cord of mSOD1 mice inversely correlated
with disease progression (8). Finally, in ALS patients the Tregs’
number and percentage, and FoxP3 expression decreased with
faster disease progression and were early predictors of ALS
progression and survival (8, 9).
Very recently, autologous infusions of expanded Treg cells
and concomitant IL-2 into patients with ALS resulted to be
safe and tolerable during early and later stages of disease in a
phase I study, where infusions seemed to slow progression rates
(10). Moreover, the study detected a correlation between Treg
suppressive function and disease progression, underscoring the
rationale underlying the use of Treg suppressive functionality as
an indicator of clinical status (10).
All these evidences convey toward a dysfunction of the
adaptive immune response during ALS. Increasing data
suggest that the systemic immune response and especially the
neuroimmune system can be modulated by gut microbiota
(GM) through the gut-brain axis, a key player in the regulation
of mutual signaling between gut microflora and central
nervous system (CNS) (11, 12) employing bidirectional
communication via neuronal, hormonal, immunologic, and
toxic signaling (13–15).
Intestinal microbiota includes a complex ecosystem with
an exceptionally high bacterial density and diversity: the
adult alimentary tract contains 1–2 kg of microbial cells of
hundred bacterial species, of which over 80% have not been
cultured (16–18).
GM communicates straightforward with the enteric immune
system, shaping immune tolerance and thus contributing to
the modulation of immune reactions during inflammation
(19). Conversely, upon pathogen invasion, dysbiosis or barrier
break, the microbe-associated molecular patterns stimulate
macrophages and dendritic cells to produce pro-inflammatory
cytokines. In turn, the cytokine activate the adaptive immune
cells, thus contributing to the breakdown of immune homeostasis
(20), and typically, determines loss of the immune cells that
keep the aggressiveness of the immune system in check, namely
Tregs (12).
Several brain biological processes may be influenced by GM
alterations. Germ free mice have been found to have an altered
density, morphology and maturity of microglia, and treatment
with a short chain fatty acids (SCFA) mixture restored the
density and morphology of CNS immune cells, suggesting that
GM can influence both the development and functions of
microglia (12, 21).
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FIGURE 1 | Picture of the study design.
In ALS, GM dysbiosis may facilitate the disease onset or drive
its progression and related outcomes, in the presence of other risk
factors. Alternately, the GM dysbiosis may be (further) altered by
the disease presence and in some individuals contribute to disease
progression, prognosis, also in terms of variable response to drug
treatments (22).
An alteration in the intestinal bacterial flora as an external
trigger could explain the rare cases of ALS in spouses or in some
clusters (23).
Based on these premises, to treat GM dysbiosis through
microbiota restoration would have the potential to interfere and
slow ALS progression (24).
Our trial aims at evaluating the biological basis of a potential
treatment for ALS (namely fecal microbiota transplantation,
FMT) in order to plan a following efficacy study.
The primary objective is to evaluate if FMT augments Tregs’
number in ALS patients, treated with FMT compared to the
control arm and measured at baseline and at month 6.
The secondary objectives include specific biological aims:
(i) comparison between treated patients and control arm of
Tregs’number and T cell subsets at different time points in blood
and gut tissue samples; (ii) comparison between treated patients
and control arm of neurophylaments and CSF cytokines and
cells; (iii) analysis of fecal and saliva samples between the two
groups to evaluate microbiota and cytokines’ profile; (iv) FMT
safety and tolerability in ALS; (v) clinical assessment (including
tracheostomy-free survival, Forced vital capacity score, ALSFRS-
R score, frequency of PEG or NIV); finally, (vi) the Quality of Life
(QoL) assessment.
METHODS AND ANALYSIS
Study Design
We are going to perform a randomized double blindmulti-center
study on FMT in ALS.
The Figure 1 summarizes the study design.
The study will include 42 ALS patients with 2:1 allocation
in 2 groups of subjects (28 FMT vs. 14 controls). Patients
will be screened in the 15 days before baseline; then they
will be randomly allocated to either FMT or control group.
Randomization will be 2:1 (FMT: controls) and will be performed
on line (using a computer-generated list of random number
that will be centrally generated in the Statistical Unit). Given
the heterogeneous ALS progression, patients will be stratified by
1FS (progression rate), calculated at randomization according
to Kimura et al. (25). Riluzole will be maintained during
the entire study duration unless adverse events or patients’
decision to withdraw. Endoscopic treatment will be performed
within 21 days from randomization. Randomization number
will not be re-used in any case. Estimated enrolment time
is 18 months.
Study Population
The study will include probable laboratory-supported, clinically
probable, or definite ALS according to revised El Escorial criteria
(sporadic and familiar). Inclusion and exclusion criteria for the
enrolment of the patients are presented in the Table 1.
Interventional Methods
Treatment will be double blinded to patients and neurologists,
but not to the endoscopist and microbiologist. ALS patients
will undergo upper GI endoscopy with small-intestine biopsies
(n◦ 4 biopsies of small intestine, performed with a standard
biopsy forces) at baseline and after 6 and 12 months. At baseline,
the patients will be randomized (2:1) to either an allogenic
(from donors) infusion of collected feces (60 grams) (FMT) in
the duodenum-jejunum or no treatment (control group). The
infusion will be performed through a standard nasojejunal tube
that will be placed during endoscopy. Fecal infusion will be
repeated at month 6. Control group patients will not receive
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TABLE 1 | Inclusion and exclusion criteria for patients.
Inclusion criteria Exclusion criteria
- Patients diagnosed with a laboratory supported, clinically “probable” or
“definite” amyotrophic lateral sclerosis according to the Revised El Escorial
criteria
- Sporadic or familial ALS
- Female or male patients aged between 18 and 70 years old
- Disease duration from symptoms onset no longer than 18 months at the
screening visit
- Patients treated with a stable dose of Riluzole (100 mg/days) for at least 30
days prior to screening
- Patients with a weight >50 kg and a BMI ≥18
- Patients with a FVC equal or more than 70% predicted normal value for
gender, height, and age at the screening visit
- Patients able and willing to comply with study procedures as per protocol
- Patients able to understand, and capable of providing informed consent at
screening visit prior to any protocol-specific procedures
- Use of effective contraception both for males and females
- Known organic gastrointestinal disease
- History of gastrointestinal malignancy; ongoing malignancies
- Use of immunosuppressive or chemotherapy within the past 2 years
- Celiac disease and/or food (e.g., lactose) intolerance
- Previous gastrointestinal surgery
- Any condition that would make endoscopic procedures contraindicated
- Acute infections requiring antibiotics
- Antimicrobial treatment or probiotics 4 weeks prior to screening
- Severe comorbidities (heart, renal, liver failure); severe renal (eGFR< 30 ml/min/1.73 m2),
or liver failure or liver aminotransferase (ALT/AST > 2x Upper limit of normal),
- Autoimmune diseases, inflammatory disorders (SLE, Rheumatoid arthritis, connective
tissue disorder) or chronic infections (HIV, hepatitis B, or C infection, Tuberculosis)
- Abuse of alcohol or drugs
- Participation in clinical trials <30 days before screening
- Existing blood dyscrasia (e.g., myelodysplasia)
- White blood cells <4,000/mm3, platelets count <100,000/mm3, hematocrit <30%
- Patients who underwent non-invasive ventilation, tracheotomy and /or gastrostomy
- Women who are pregnant or breastfeeding
BMI, Body Mass Index; FVC, Forced Vital Capacity; eGFR, estimated Glomerular Filtration Rate; ALT, alanine aminotransferase; AST, aspartate aminotransferase; SLE, Systemic
Lupus Erythematosus.
any treatment (at baseline or at month 6), but will remain
blind to treatment because of sedation due to small-intestine
biopsies. Fecal microbiome will be diluted in saline solution
(200ml) and infused at 30 ml/min speed (whole amount of the
performance: 15min). Fresh feces for the FMT will be obtained
by habitual healthy donors for Clostridium difficile infection.
The Table 2 shows the blood and stool testing for donators
and the general selection criteria. Before preparation, sample
donation will be always analyzed by rapid molecular test to detect
intestinal pathogens.
Analysis of T cell sub-populations will be performed both in
peripheral blood and gut mucosa: Treg, Th17 cells, effector, and
central memory cells.
At the end of the treatment period, further 6 months will be
required as a follow-up period. This time is intended to assess
late adverse events (AEs) and later biological or clinical effects
of transplantation.
Sample Size Estimation
Sample size was calculated considering as primary outcome
measure the proportion of patients, in the transplantation group
with respect to controls, displaying a “positive response” intended
as an increase in the proportion of Treg by at least 20%. The
null hypothesis states that FMT does not ameliorate significantly
the proportion of positive responses in treated patients after the
second FMT round, compared to their baseline and to control
group. The alternative hypothesis is that FMT gives a proportion
of positive responses in at least 50% of treated patients compared
to a maximum 5% of positive responses in patients of the control
group. The study was designed to refuse the null hypothesis with
an alpha error of 0.05 and a power of 0.80 according to previously
published statistical methods (26) and to known levels of Tregs in
ALS patients, that typically display a slight reduction of Treg %
(mean ± standard deviation: 2.1 ± 0.7) with respect to healthy
controls with fast progressors patients having on average 31%
fewer Treg (8, 27).
For this purpose, a population of 39 patients randomized
in two treatment arms would suffice; taking into account an
average drop out of 10%, a recruitment of 42 patients will
be needed.
Outcome Measures
Primary outcome measure is the modification from baseline to
month 6 in Treg number in transplanted ALS patients compared
to the control arm (26).
Secondary outcome measures include the following:
X Biological outcome measures:
– Change from baseline to month 3, 6, 9, 12 of the T cell
distribution especially the ratio Treg/Th1 or Treg/Th17
comparing FMT arm and control arm (both blood—at
each time point, and small intestine—only at 6 and 12).
– Changes from baseline tomonth 3, 6, 9, 12 in inflammatory
status (cytokine profile) comparing FMT and control arm
(in blood and feces at each time point, and in CSF at
month 6).
– Changes from baseline to month 3, 6, 9, 12 between FMT
arm and control arm in the following biomarkers:
creatinine, albumin, CK, vitamin D, plasma/CSF
neurofilament heavy/light chain protein.
– Biological modifications from baseline to month 6 and
12 in the composition of saliva, gut and fecal microbiota
(including SCFA) comparing FMT and control arm.
X Safety: will be assessed in FMT and control arm considering
the occurrence of AEs and modifications in physical
examination, vital signs, body weight, and laboratory
tests (biochemistry, hematology) during and following
the treatment.
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TABLE 2 | Criteria for donors’ selection.
EXCLUSION CRITERIA
Infectious diseases risk Gastrointestinal, metabolic and
neurological disorders
Drugs that can impair gut microbiota
composition
◮ History of, or known exposure to, HIV, HBV, HCV,
syphilis, HTLV1-2, tuberculosis, malaria,
trypanosomiasis
◮ Known systemic infection not controlled at the time
of donation
◮ Use of illegal drugs
◮ Risky sexual behavior
◮ Previous reception of tissue/organ transplant
◮ Recent (<12 months) reception of blood products
◮ Recent (<6 months) needle stick accident
◮ Recent (<6 months) body tattoo, piercing, earring,
acupuncture
◮ Recent medical treatment in poorly hygienic
conditions
◮ Risk of transmission of prions diseases
◮ Recent parasitosis or infection from rotavirus, Giardia
lamblia, and other microbes with GI involvement
◮ Recent (<6 months) travel in tropical countries,
countries at high risk of communicable diseases or
traveller’s diarrhea
◮ Recent (<6 months) history of vaccination with a live
attenuated virus, if there is a possible risk of
transmission
◮ Healthcare workers (to exclude the risk of
transmission of multidrug-resistant organisms)
◮ Individual working with animals (to exclude the risk of
transmission of zoonotic infections)
◮ History of inflammatory bowel syndrome or
disease, functional chronic constipation,
coeliac disease, other chronic GI disorders
◮ History of chronic, systemic autoimmune
diseases with GI involvement
◮ History of, or high risk for, GI cancer
or polyposis
◮ Recent appearance of
diarrhea, hematochezia
◮ History of
neurological/neurodegenerative diseases
◮ History of psychiatric conditions determining
mental health instability or incapacity
◮ Overweight and obesity (body mass
index >25)
◮ Recent (<3 months) exposure to antibiotics,
immunosuppressants, chemotherapy
◮ Chronic therapy with proton pump inhibitors
ISSUES TO ADDRESS ON THE SAME DAY OF DONATION TO CHECK ANY RECENTLY ONSET OF HARMFUL EVENTS
The following issues, if present, contraindicate donation on the same day on which they are assessed:
◮ Newly appeared GI signs and symptoms, for example, diarrhea, nausea, vomiting, abdominal pain, jaundice
◮ Newly appeared illness or general signs as fever, throat pain, swollen lymph nodes
◮ Use of antibiotics or other drugs that may impair gut microbiota, new sexual partners, or travels abroad since the last screening
◮ Recent ingestion of a substance that may result harmful for the recipients
◮ Travel in tropical areas—contact with human blood (sting, wound, showing, piercings, tattoos)—sexual high-risk behavior
◮ Diarrhea (more than three loose or liquid stools per day) among members of the entourage (including children) of the donor
BLOOD AND STOOL TESTING TO CHECK DONORS FOR ANY POTENTIALLY TRANSMITTABLE DISEASE
General blood testing General stool testing
◮ Cytomegalovirus
◮ Epstein-Barr virus
◮ Hepatitis A
◮ HBV
◮ HCV
◮ Hepatitis E virus
◮ Syphilis
◮ HIV-1 and HIV-2
◮ Entamoeba histolytica
◮ Complete blood cell count with differential
◮ C-reactive protein and erythrocyte sedimentation rate
◮ Albumin
◮ Creatinine and electrolytes
◮ Aminotransferases, bilirubin,
gamma-glutamyltransferase, alkaline phosphatase
◮ Detection of Clostridium difficile
◮ Detection of enteric pathogens, including Salmonella, Shigella
◮ Campylobacter, Escherichia coli O157 H7, Yersinia, vancomycin-resistant enterococci,
methicillin-resistant Staphylococcus aureus, Gram-negative multidrug-resistant bacteria
◮ Norovirus
◮ Antigens and/or acid fast staining for Giardia lamblia and Criptosporidium parvum
◮ Protozoa (including Blastocystis hominis) and helminths
◮ Fecal occult blood testing
(Continued)
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TABLE 2 | Continued
Blood testing in specific situations Stool testing in specific situations
◮ Human T-lymphotropic virus types I and II antibodies
Strongyloides stercoralis
◮ Detection of Vibrio cholera and Listeria monocytogenes
◮ Antigens and/or acid fast staining for Isospora and Microsporidia
◮ Calprotectin
◮ Helicobacter pylori fecal antigen
◮ Rotavirus
X Clinical outcome measures:
The following clinical variables will be compared between
FMT and control arm:
– Change from baseline to each time point (month 1, 3, 6, 9,
12) of ALSFRS-R.
– Survival from onset and randomization to death
or tracheotomy.
– Change of Forced Vital Capacity (FVC) from baseline to
each time point (month 1, 3, 6, 9, 12).
– Frequency of procedures (PEG, NIV, IV) from baseline to
month 3, 6, 9, 12.
X Quality of life: will be assessed as the change in absolute
and relative values of the Amyotrophic Lateral Sclerosis
Specific Assessment Questionnaire (ALSAQ40) from baseline
to month 6 and 12 in FMT and control arm.
The Table 3 shows the study flow chart.
Adverse Events and Safety
According to Directive 2004/23/EC (implemented in Italy with
D.Lgs 191/2007):
– “Serious adverse event” (SAE) means any untoward
occurrence associated with the procurement, testing,
processing, storage, and distribution of tissues and cells that
might lead to the transmission of a communicable disease,
to death or life-threatening, disabling, or incapacitating
conditions for patients or which might result in, or prolong,
hospitalization, or morbidity (https://www.hta.gov.uk/
policies/human-application-adverse-event-and-reaction-
saears-reporting; http://www.sc-toolkit.ac.uk/displaycontent.
cfm?widCall1=customWidgets.content_view_1&cit_id=84).
– “Serious adverse reaction” (SAR) means an unintended
response, including a communicable disease, in the donor or
in the recipient associated with the procurement or human
application of tissues and cells that is fatal, life-threatening,
disabling, incapacitating, or which results in, or prolongs,
hospitalization or morbidity (https://www.hta.gov.uk/
policies/human-application-adverse-event-and-reaction-
saears-reporting; http://www.sc-toolkit.ac.uk/displaycontent.
cfm?widCall1=customWidgets.content_view_1&cit_id=84).
The existing studies suggest that FMT is a safe therapy,
with few serious adverse events reported. There have been
individual reports of peripheral neuropathy, Sjogren syndrome,
idiopathic thrombocytopenic purpura, microscopic colitis,
contact dermatitis, rheumatoid arthritis, obesity, bacteremia,
and ulcerative colitis flare after FMT (24). In one meta-analysis,
the overall incidence rate of adverse events after FMT was 28.5%.
The commonest FMT-attributable adverse event was abdominal
discomfort; also diarrhea, transient fever, nausea, vomiting, and
constipation were other common symptoms associated to FMT
(24, 28–31).
For these mild adverse events, investigators will treat
symptoms according to the usual clinical practice. In case of
symptoms that could be considered severe or life threating, the
investigator will have to inform the sponsor immediately (within
24 h by fax using a SAE form) and second FMT round may
be avoided accordingly to the local investigator’s judgment. In
accordance with the legislative requirements, Centers will be
requested to report immediately from their awareness any SAE or
SAR occurring during the trial and coordinating center will send
Completed forms by email to Italian National Transplantation
Center (CNT).
The coordinating Center will be responsible for appropriate
AE reporting to the regulatory authorities (CNT) every 6months;
investigators will be responsible for reporting to appropriate
Ethic Committee. In case of death, a clinical report will
be prepared by the caring investigator together with SAE
form; in case of autopsy, autopsy report will be added to
study documentation.
The trial will be stopped in case of 30% excess in the treating
group of the following AEs: peritonitis, upper gastrointestinal
hemorrhage, sepsis, bacteremia. Instead, the next toxicities will be
considered acceptable: diarrhea, abdominal cramping and pain,
nausea, vomiting, flatulence, fever, constipation, dizziness, sore
throat, rhinorrhea, bloating, nasal stuffiness, urinary infections,
headache, mild/moderate blood cells alterations; elevated
CRP, rashes, urticaria, dermatoses, dermatitis (mild/moderate
severity), elevated aminotransferase/alkaline phosphatase, loss of
appetite, colitis/gastroenteritis.
Data Recording and Data Monitoring
An electronic case report form (CRF) will be prepared for
data recording.
A certified contract research organization (CRO) will be in
charge for monitoring the study.
The studymonitor indicated by the coordinating center will be
in contact with the investigators and will conduct a visit to each
Center to discuss and/or collect data. The Monitor will conduct
a visit before the start of the study to discuss the protocol and
obligations of the investigators and sponsor. Investigators of each
center are required to allow the Monitor to conduct the site visit,
the study-end visit and the site closure visit.
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TABLE 3 | Study flow chart.
Pre-treatment Treatment Follow up Study end
Examinations Screening Baseline
(W0)
FMT 1
(Rome)
M1 M3 M6 FMT 2
(Rome)
M7 M9 M12 (Rome) M12
Time window <3 weeks
from
screening
<4 weeks
from
screening
±3 days ±3 days ±3 days ±7 days ±7 days ±7 days ±7 days ≥7 days <4
weeks from
M12
Informed consent x
Medical history x
Inclusion exclusion
criteria
x
Patient able to
understand and
follow procedures
x
FMT x x
CLINICAL ASSESSMENT
Neurological
examination
x x x x x x x x
ALSFRS-R x x x x x x x x
FVC x x x x x x x x
MRC x x x x x x x x
BMI x x x x x x x x x x x
SAFETY ASSESSMENT
Adverse events x x x x x x x
Vital signs x x x x x x x x x x x
Physical examination x x x x x x x x x x x
Concomitant
medications
x x x x x x x x x x x
Chest X-ray x (1)
ECG x (1)
Hematology x x x x x x x
Biochemistry x x x x x x x
Urinalysis x x x x x x x
Pregnancy test x
Infectious markers x
Fecal calprotectin x x x
BIOLOGICAL ACTIVITY
Treg x x x x x x x
Lymphocytes
phenotype
x x x x
Fecal and saliva
samples (microbiota)
x x x
Gut tissue x x x
CSF x x
Peripheral
biomarkers
x x x x x
QUALITY OF LIFE ASSESSMENT
ALSAQ40 x x x
(1) If not done at diagnosis or in the last 12 months.
FMT, Fecal Microbial Transplantation; M, Month; MRC, Medical Research Council; FVC, Forced Vital Capacity; BMI, Body Mass Index; ALSFRS-R, Revised ALS Functional Rating Scale;
ECG, Electrocardiogram; CSF, Cerebrospinal Fluid; ALSAQ40, ALS Specific Assessment Questionnaire; W, week.
The Investigators will make all pertinent records available
including original medical documents for inspection by
regulatory authorities.
Copies of the protocol, subject identification codes, electronic
Case Report Form, source data, Informed Consent Form and
other documents related to the study conduction and support
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the data collected from each subject will be stored for the
maximum period of time as required by the study centers. No
study document should be destroyed.
Originals of all documentation and copies of outgoing
correspondence concerning the study will be stored and retained
by the Sponsor in a safe area in the Trial Master File.
Role of Participating Centers
This multicenter study will involve nine Italian Units: six referral
ALS Centers (located in Florence, Chieti, Perugia, Modena, and
Rome), three renowned laboratories, one endoscopy service and
a statistical unit.
ALS is a rare disease with fast progression and no
effective treatment, which requires a solid methodological,
clinical approach, and biological background for clinical
trials conduction.
Each clinical center is expected: (I) to randomize at least
seven patients according to including and excluding criteria
in 18 months; (II) to provide one principal investigator
to evaluate including and excluding criteria, and assess
primary and secondary outcomes; (III) to adhere to ALS
management guidelines of the European Federation of
Neurological Societies(in particular as regards ventilation
and nutrition issues).
The analysis of biomarkers will be centralized and performed
in two internationally renowned laboratories Laboratory of
Microbiology Policlinico Gemelli in Rome and Laboratory
of Immunology, Department of Experimental and Clinical
Medicine—University of Florence, and FMT will be performed
at Policlinico Gemelli in Rome, a leading European Center for
this kind of treatment.
Data Analysis
Data will be collected by investigators through electronic CRF,
which will be conveyed to the trial database. At trial completion,
data from the locked database will be extracted for analysis by an
expert statistician.
Separate analyses will be performed in:
1. All randomized subjects receiving at least 1 FMT (Intention-
to-treat population).
2. All randomized subjects excluding protocol deviations (Per
protocol population).
As far as biological activity is concerned, immune response to
FMT will be analyzed as a difference in positive response to
FMT between the control group and the FMT group, assessed by
comparison of proportion of patients in the two groups showing a
mean Tregs increase by at least 20%, between baseline andmonth
6 measurements.
Mean values of different T, B, NK cell subpopulations,
neurodegeneration biomarkers, and cytokines will be assessed
and mean differences in plasma concentrations between the
two treatment arms will be calculated using t-test or Wilcoxon-
Mann-Whitney test as previously reported (26). ANOVA will
be used for assessing the mean change over time for the same
variables as above, with treatment as between-subjects factor and
time as within-subjects factor. Different models will be used, each
with a different biomarker of activity as the dependent variable.
Models will be adjusted for any unbalanced distribution of the
main prognostic factors (e.g., age) between the two treatment
arms, according to previously published statistical methods (26).
Analysis of microbiota will be performed with
specific software.
Record of any AE and SAE will be kept for every subject
receiving at least one round of FMT till the study completion,
performing safety analysis accordingly.
As for clinical outcome measures, we will compare ALSFRS-
R total score and subscores (bulbar, respiratory, gross, and fine
motor) changes from baseline to each time point in treatment
arm vs. control arm. Frequency of procedures (PEG, NIV, IV)
will be compared from baseline to each time point in treatment
vs. control arm. The comparison of clinical endpoint among
arms will be carried out by using the logistic regression model.
Results will be presented as odds ratios (OR) and 95%C.I. FMT
will be considered effective in relation to controls whether the
OR of positive results will provide a p < 0.05. Change in
FVC during the study will be analyzed using a mixed model
for repeated measures (MMRM). Difference between treatment
groups and two-sided 95%CI will be estimated .Log-rank tests via
Kaplan-Meier method will be employed to compare differences
in tracheostomy-free survival between the two treatment arms
(from onset and from randomization), while Cox’s proportional
hazard model will be used for adjusting for any possible
unbalanced prognostic factors. Statistical significance will be
set at 0.05 level for a two-tailed test. Last observation will be
considered for patients with missing data.
Given the short duration of the study, an interim analysis
of efficacy data is not scheduled. Nevertheless, to address safety
concerns, a report including all relevant clinical data of patients
will be sent by the Statistics Unit to an independent Data and
Safety Monitoring Board for scheduled DSMB meetings (also
through Skype) when 14 patients would have completed the
second treatment and then every 6 months.
Ethics Approval
This study has been approved by Comitato Etico Area Vasta
Emilia Nord on July 2018 (prot. n. 0010722/18), and by National
Transplantation Center on 29 March 2019.
The trials has been registered in clinicaltrials.gov
(NCT03766321).
DISCUSSION
Choice of Treatment
FMT dates back to fourth-century China, as a report of
a traditional Chinese medicine doctor describing a patient’s
recovery from food poisoning and severe diarrhea after treatment
with oral human fecal suspension (32). Further uses of this kind
of treatment have been described since the sixteenth century
(32–35) mainly through retention enema.
More recently, FMT has emerged as a safe and effective
treatment for the management of recurrent, and possibly
refractory, Clostridium Difficile Infection (CDI) by restoring gut
microbial diversity, with cure rates >85% (36). Currently, the
Frontiers in Neurology | www.frontiersin.org 8 September 2019 | Volume 10 | Article 1021
Mandrioli et al. Microbiota Transplantation in ALS
FMT has been approved for the treatment of this condition, for
which it has had unanimously excellent results (24, 37, 38).
Since a perturbed microbiota is associated with several
diseases, it is conceivable that microbiota restoration therapies
could be useful in their management (24). The importance of
“healthy” gut microbiome has been shown in oncology, an in
detail in relation to response to antitumor treatment (39–41). In
addition, a few papers have recently highlighted a potential link of
gut dysbiosis and neurological diseases (41–45), such as multiple
sclerosis (46, 47), Parkinson’s Disease (48, 49), and Alzheimer’s
disease (50, 51).
For this reason, there are studies now testing FMT potentiality
to treat multiple sclerosis, myasthenia gravis, Parkinson’s Disease,
and epilepsy (22, 52).
Some preliminary data place the theoretical basis for a
GM involvement in ALS because immune system, which plays
a key role at least in ALS progression, can be modulated
through gut-brain axis. Indeed, the gut environment favors
the generation of autoreactive T-cells with unique regulatory
functions, important for preventing CNS autoimmunity (53).
Some commensal bacteria can induce Tregs development and
FMT determine Tregs’ increase (54).
Moreover, alterations in GM composition in ALS have been
reported in previous studies. Fang et al. (55) found a significantly
increased population of harmful microorganisms (genus
Dorea) with reduced population of beneficial microorganisms
(genus Oscillibacter, Anaerostipes, Lachnospiraceae) in ALS
patients (45). The authors suggested that the imbalance in
intestinal microflora constitution may cause a pro-inflammatory
dysbiosis that may alter the intestinal epithelial barrier,
promoting immune/inflammatory responses with a major role
in ALS pathogenesis.
Another study (56) detected a higher amount of E. Coli and
Enterobacteria and a low presence of total yeast in the GM
composition of ALS patients with respect to healthy controls.
Two pre-clinical researches, performed in G93A animals,
studied the correlation between gut dysbiosis, altered intestinal
permeability and enteric inflammatory/neurogenic responses
(12). Wu et al. (57) found signs of leaky intestine in a G93A
transgenic mouse having an augmented gut permeability due to
impairment of the intestinal tight junction structure and related
protein expression, if compared to wild-type mice (57). The same
model showed a reduced number of and an altered function
of epithelial Paneth cells, that impact the GM and have a role
in the innate immune response, and, as far as concerns GM
composition, a lower abundance of butyrate-producing bacteria
such as Butyrivibrio fibrisolvens, Escherichia coli, and Firmicutes
was detected. Finally, shifts in the gut microbiome included.
Likewise, Zhang et al. (58) reported a correlation between
gut dysbiosis and morphofunctional alterations of intestinal
permeability in the same model, since the earliest stages of the
disease. They demonstrated the presence of SOD1 aggregates,
which are distinctive of ALS associated to SOD1 mutations
in animal models and in patients, not only in neurons and
skeletal muscle, but also in the intestine of ALS mice and human
intestinal epithelial cells. Moreover, the authors observed that,
following treatment with 2% butyrate (a natural bacterial product
able to restore the intestinal microbial homeostasis), G93A mice
restored GM balance and intestinal epithelial barrier integrity,
besides they showed improved central and peripheral symptoms
of the disease, prolonged survival, and slowing of weight loss (58).
These data suggested that changes in GM, impaired intestinal
permeability and enteric inflammation represent one of the
earliest events in ALS. However, these findings did not allow to
firmly establish whether the alterations of the enteric bacteria
neuro-immune network contribute to the ALS pathophysiology,
or whether they happen as a consequence of the cascade of events
accompanying neurodegeneration (12).
In a recent study, SOD1-Tg mice prone to ALS showed a
vivarium-dependent pre-symptomatic dysbiosis and an altered
configuration of metabolites, occurring with a disease worsened
under conditions of germ-free or broad-spectrum antibiotic
treatment (59). The authors could correlate some species in gut
microbiota with ALS severity and supplementation with certain
species changed mice phenotype (59).
In this context, FMT may act against ALS progression,
by regulation of the mutual signaling between gut microflora
and CNS (11), employing bidirectional communication (via
neuronal, hormonal, immunologic, and toxic signaling) (14,
15). Moreover, direct communication through the vagus
nerve, changes in tryptophan and norepinephrine metabolism,
production and absorption of neuroactive metabolites, immune
activation through molecular mimicry and the direct production
of neurotoxins (22) may be useful in controlling ALS disease)
(13). Nearly 30% of ALS patients show autonomic dysfunctions
with demonstrated involvement of the intermediolateral columns
and the Onuf nucleus. The vagal nerve could be a route
for GM and brain communication (60). Of note, GM has
been found to interact with ENS-vagus nerve pathways (61)
because, bacterial derived-neurotransmitters and neuropeptides
can activate directly myenteric neurons, which, through vagal
nerve ascending fibers, deliver nerve inputs to the brain (12, 62).
Enteric bacteria and their metabolites (especially the
SCFAs) can indeed induce enterochromaffin cells to release
neurotransmitters and neuropeptides (including peptide YY,
neuropeptide Y, cholecystokinin, glucagon-like peptide-1 and−2,
and substance P), which, in turn, can reach the brain through
blood circulation and have an effect on CNS functions (12). In
addition, the intestinal epithelium regulates the spread of specific
bacterial products (e.g., SCFAs, vitamins or neurotransmitters,
such as acetylcholine, dopamine, noradrenaline, gamma-
aminobutyric acid, or serotonin) into the circulatory system,
that, in turn, may arrive to the CNS (11, 12). In this way,
circulating microbiota-derived metabolites, neuropeptides, and
neurotransmitters can enter the CNS and so directly influence
the neurobiology and the ALS pathology.
Individual case reports of ALS patients documented benefits
as a result of FMT (63). This research field is therefore
highly innovative and is gathering increasing interest from the
international scientific community (13, 43).
Anticipated Results
Our trial aims at evaluating the biological bases of FMT as a
potential treatment for ALS in order to plan a following efficacy
study on fecal microbiota transplantation for this disease.
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We will carry on the first clinical trial with FMT in ALS
patients; this is a highly innovative therapeutic approach that
will give information about safety and tolerability of FMT. We
will assess biological FMT effects in ALS and we will have some
preliminary clinical data about the possibility that microbiota-
based treatment approaches can represent a new therapeutic
target for ALS.
The strength of our study is represented by a large panel of
biological tests aimed at clarifying the role of enteric bacteria-
neuro-immune network in ALS patients, since the earlier stages
of the disease (patients will be enrolled only if disease onset
<18 months), through exploration of immunological patterns in
blood, CSF, saliva, and feces, along with small intestine tissue
in ALS patients treated or not with FMT. These data will be
correlated with composition of saliva, gut and fecal microbiota at
different time points, allowing to contribute to the understanding
of ALS pathophysiology in terms of microbiota involvement
in the causal ALS process, or as a consequence of the central
neurodegenerative processes.
Moreover, comprehensive patients’ clinical phenotyping will
be accomplished according to the study protocol, allowing to
establish correlations between precise groups of progressors
and the GM system, which has never been explored in
terms of biomarker of disease progression. Further analyses
considering subgroups of patients on the basis of Treg cells or
microbiota population will help to better understand underlying
pathomechanisms of the disease and to plan more targeted
advanced studies.
The sampling from different matrices will grant a full view
of the modifications operated by FMT and in the future, more
accessible biomatrices such as saliva might be considered for
monitoring disease status in ALS patients. This trial has the
potential to give preliminary results to carry on further larger
studies aimed at assessing FMT effectiveness in ALS treatment.
ETHICS STATEMENT
This RCT will be performed in compliance with the
Declaration of Helsinki, as amended by the 64th WMA
General Assembly, Fortaleza, Brazil, October 2013, and with the
current ICHGCP-guidelines.
The study has been approved by lead ethics committee
(Comitato Etico Area Vasta Emilia Nord on July 2018) and has
been submitted to local ethics committees. The study obtained
the approval of National Transplantation Center and Superior
Council of Health (as competent authorities for experimental
transplantation) on March 2019.
All subjects, after comprehensive written and verbal
information, will date and sign an approved Informed Consent
Form (ICF) explaining rationale, procedures, duration, possible
risks and benefits associated with the study. The patient will be
informed that participation in the study is voluntary and that
refusal to participate or withdrawal from the study, at any time,
will not be associated to any penalty, or loss of benefits. An
insurance company will provide insurance coverage for damages
to patients involved in the trial. Principal Investigator will be
supplied with all data concerning the insurance company and
policy number. Finally, the data privacy and confidentiality
will be treated according to European and Italian law. An
Independent Ethics Advisory Board (IEAB) has been established,
to address ethics concerns that could arise during the study,
focusing especially to informed consent form. For this reason
patient information sheet will be given to the candidate
patient at least 15 days before the collection of the ICF. In
the patient information sheet the patient will find a telephone
number of the IEAB that he/she could call to have independent
information. Furthermore, when the neurologist will give the
patient information sheet to the patient, the investigator will
advise IEAB of a possible enrollment to allow IEAB member to
be present at the moment of the ICF collection. An independent
Data Safety and Monitoring Board (DSMB) has been established
too, to address safety and efficacy concerns that could arise
during the study. Reports including all relevant clinical data
of patients will be sent by the Statistics Unit of the University
of Modena to the independent DSMB for scheduled DSMB
meetings when 14 patients have done the second treatment
and subsequently after every 6 months. All the partners will
guarantee the dissemination and exploitation of the scientific
results within the consortium and externally (international
conferences, publications, dedicated workshops with patients).
The results will be presented during national and international
neurological and ALS meetings and workshops. Results will
be published on www.clinicaltrials.gov and in peer-reviewed
international journals.
AUTHOR CONTRIBUTIONS
AA, JM, and LM contributed to conception and design of the
study. RD’A contributed to design of the study and planned
statistical analysis. EZ and JM wrote the first draft of the
manuscript. AA, EN, EZ, GC, LM, RD’A, and TS wrote
sections of themanuscript. All authors contributed tomanuscript
revision, read, and approved the submitted version.
FUNDING
This project was supported by the Italian Ministry of Health,
Grant-No. RF-2016-02361616.
ACKNOWLEDGMENTS
The authors acknowledge FETRALS Working Group (see
FETRALS Working Group). The authors also acknowledge the
contribution of the members of the independent Data Safety
Monitoring Board (Prof. Josbert Keller, Dr. Ettore Beghi, Prof.
Reetta Satokari) and of the Independent Ethics Advisory Board
(Prof. Antonio G. Spagnolo, Dr. Gabriele Semprebon).
FETRALS WORKING GROUP
Neurology Unit, S. Agostino Estense Hospital, Department of
Neuroscience, Azienda Ospedaliero Universitaria di Modena,
Frontiers in Neurology | www.frontiersin.org 10 September 2019 | Volume 10 | Article 1021
Mandrioli et al. Microbiota Transplantation in ALS
Modena, Italy; Department of Biomedical, Metabolic and Neural
Sciences, University of Modena and Reggio Emilia, Modena,
Italy: Jessica Mandrioli, Nicola Fini, Elisabetta Zucchi, Annalisa
Gessani, Antonio Fasano, Ilaria Martinelli.
Laboratory of Immunology, Department of Experimental
and Clinical Medicine, University of Florence, Florence, Italy:
Amedeo Amedei, Elena Niccolai, Federica Ricci.
Scienze gastroenterologiche, endocrino-metaboliche e
nefro-urologiche, Fondazione Policlinico Universitario A.
Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome,
Italy; Istituto di Medicina Interna e Geriatria, Università
Cattolica del Sacro Cuore, Rome, Italy: Giovanni Cammarota,
Antonio Gasbarrini.
Instituto di Microbiologia, Università Cattolica del Sacro
Cuore, Rome, Italy Dipartimento di Scienze di Laboratorio ed
Infettivologiche, Fondazione Policlinico Universitario A. Gemelli
IRCCS, Rome, Italy—Luca Masucci, Teresa Spanu, Gianluca
Quaranta, Maurizio Sanguinetti.
Statistics Unit, Department of Medical and Surgical
Sciences for Children & Adults, University of Modena
and Reggio Emilia, Modena, Italy: Roberto D’Amico,
Roberto Vicini.
Neuromuscular Omnicenter (NEMO), Fondazione Serena
Onlus—Fondazione Policlinico A. Gemelli, Rome, Italy, &
Institute of Neurology, Catholic University of the Sacred Heart,
Fondazione Policlinico A. Gemelli, Rome, Italy: Mario Sabatelli,
Amelia Conte.
Institute of Neurology, Policlinico Campus Bio-Medico,
Rome, Italy: Vincenzo di Lazzaro.
Department of Neurological and Psychiatric sciences
(NEUROFARBA), University of Florence, Florence, Italy, &
Careggi University Hospital, Neurology unit, Florence, Italy:
Sabrina Mata, Sandro Sorbi.
Neurology Clinic, “S Annunziata” Hospital, Chieti, Italy,
& Department of Neuroscience and Imaging, University “G.
d’Annunzio” of Chieti-Pescara, Chieti, Italy:Margherita Capasso,
Marco Onofrj.
Perugia Hospital, Neurophysiopathology Unit, Azienda
Ospedaliera di Perugia, S. Andrea delle Fratte, 06156 Perugia,
Italy: Teresa Anna Cantisani, Paola Brunori.
REFERENCES
1. Oskarsson B, Gendron TF, Staff NP. Amyotrophic lateral
sclerosis: an update for 2018. Mayo Clin Proc. (2018) 93:1617–28.
doi: 10.1016/j.mayocp.2018.04.007
2. Rossi S, Cozzolino M, Carrì MT. Old versus new mechanisms in the
pathogenesis of ALS. Brain Pathol. (2016) 26:276–86. doi: 10.1111/bpa.12355
3. Geloso MC, Corvino V, Marchese E, Serrano A, Michetti F, D’Ambrosi N. The
dual role of microglia in ALS: mechanisms and therapeutic approaches. Front
Aging Neurosci. (2017) 9:242. doi: 10.3389/fnagi.2017.00242
4. Boillée S, Yamanaka K, Lobsiger CS, Copeland NG, Jenkins NA, Kassiotis G,
et al. Onset and progression in inherited ALS determined by motor neurons
and microglia. Science. (2006) 312:1389–92. doi: 10.1126/science.1123511
5. Tiemessen MM, Jagger AL, Evans HG, van Herwijnen MJ, John S,
Taams LS. CD4+CD25+Foxp3+ regulatory T cells induce alternative
activation of human monocytes/macrophages. PNAS. (2007) 104:19446–51.
doi: 10.1073/pnas.0706832104
6. Liu G, Ma H, Qiu L, Li L, Cao Y, Ma J, Zhao Y. Phenotypic and functional
switch of macrophages induced by regulatory CD4+CD25+ T cells in mice.
Immunol Cell Biol. (2011) 89:130–42. doi: 10.1038/icb.2010.70
7. Schetters STT, Gomez-Nicola D, Garcia-Vallejo JJ, Van Kooyk Y.
Neuroinflammation: microglia and T cells get ready to tango. Front
Immunol. (2018) 8:1905. doi: 10.3389/fimmu.2017.01905
8. Beers DR, Henkel JS, Zhao W, Wang J, Huang A, Wen S, et al. Endogenous
regulatory T lymphocytes ameliorate amyotrophic lateral sclerosis in mice
and correlate with disease progression in patients with amyotrophic lateral
sclerosis. Brain. (2011)134:1293–314. doi: 10.1093/brain/awr074
9. Henkel JS, Beers DR, Wen S, Rivera AL, Toennis KM, Appel
JE, et al. Regulatory T-lymphocytes mediate amyotrophic lateral
sclerosis progression and survival. EMBO Mol Med. (2013) 5:64–79.
doi: 10.1002/emmm.201201544
10. Thonhoff JR, Beers DR, Zhao W, Pleitez M, Simpson EP, Berry JD, et al.
Expanded autologous regulatory T-lymphocyte infusions in ALS: a phase I,
first-in-human study. Neurol Neuroimmunol Neuroinflamm. (2018) 5:e465.
doi: 10.1212/NXI.0000000000000465
11. Fung TC, Olson CA, Hsiao EY. Interactions between the microbiota, immune
and nervous systems in health and disease. Nat Neurosci. (2017) 20:145–55.
doi: 10.1038/nn.4476
12. Pellegrini C, Antonioli L, Colucci R, Blandizzi C, Fornai M. Interplay
among gut microbiota, intestinal mucosal barrier and enteric neuro-immune
system: a common path to neurodegenerative diseases? Acta Neuropathol.
(2018)136:345–61. doi: 10.1007/s00401-018-1856-5
13. ALSUntangled Group. ALS untangled no. 21: fecal transplants.
Amyotroph Lateral Scler Frontotemporal Degener. (2013)14:482–5.
doi: 10.3109/21678421.2013.814981
14. Bienenstock J, Kunze W, Forsythe P. Microbiota and the gut-brain axis. Nutr
Rev. (2015) 73 (Suppl. 1):28–31. doi: 10.1093/nutrit/nuv019
15. Mayer EA, Tillisch K, Gupta A. Gut/brain axis and the microbiota. J Clin
Invest. (2015)125:926–38. doi: 10.1172/JCI76304
16. Backhed F, Ley RE, Sonnenburg JL, Peterson DA, Gordon JI. Host-
bacterial mutualism in the human intestine. Science. (2005) 307:1915–20.
doi: 10.1126/science.1104816
17. Conway PL. Development of intestinal microbiota. In: Mackie RI,White
BA, Isaacson RE, editors. Gastrointestinal Microbiology, Vol.2. New
York, NY: Chapman & Hall Microbiology Series (1997). p. 3–38.
doi: 10.1007/978-1-4757-0322-1_1
18. Eckburg PB, Bik EM, Bernstein CN, Purdom E, Dethlefsen L, Sargent M, et al.
Diversity of the human intestinal microbial flora. Science. (2005) 308:1635–8.
doi: 10.1126/science.1110591
19. Shi N, Li N, Duan X, Niu H. Interaction between the gut
microbiome and mucosal immune system. Mil Med Res. (2017) 4:14.
doi: 10.1186/s40779-017-0122-9
20. Maynard CL, Elson CO, Hatton RD, Weaver CT. Reciprocal interactions of
the intestinal microbiota and immune system. Nature. (2012) 489:231–41.
doi: 10.1038/nature11551
21. Erny D, Hrabeˇ de Angelis AL, Jaitin D, Wieghofer P, Staszewski O, David E,
et al. Hostmicrobiota constantly control maturation and function ofmicroglia
in the CNS. Nat Neurosci. (2015) 18:965–77. doi: 10.1038/nn.4030
22. Tremlett H, Bauer KC, Appel-Cresswell S, Finlay BB, Waubant E. The gut
microbiome in human neurological disease: a review. Ann Neurol. (2017)
81:369–82. doi: 10.1002/ana.24901
23. Sabel CE, Boyle PJ, Loytonen M, Gatrell AC, Jokelainen M, Flowerdew
R, et al. Spatial clustering of amyotrophic lateral sclerosis in Finland at
place of birth and place of death. Am J Epidemiol. (2003) 157:898–905.
doi: 10.1093/aje/kwg090
24. Khanna S. Microbiota replacement therapies: innovation in gastrointestinal
care. Clin Pharmacol Ther. (2018) 103:102–11. doi: 10.1002/cpt.923
25. Kimura F, Fujimura C, Ishida S, Nakajima H, Furutama D, Uehara H, et al.
Progression rate of ALSFRS-R at time of diagnosis predicts survival time in
ALS. Neurology. (2006) 66:265–7. doi: 10.1212/01.wnl.0000194316.91908.8a
Frontiers in Neurology | www.frontiersin.org 11 September 2019 | Volume 10 | Article 1021
Mandrioli et al. Microbiota Transplantation in ALS
26. Mandrioli J, D’Amico R, Zucchi E, Gessani A, Fini N, Fasano
A, et al. Rapamycin treatment for amyotrophic lateral sclerosis:
protocol for a phase II randomized, double-blind, placebo-controlled,
multicenter, clinical trial (RAP-ALS trial). Medicine. (2018) 97:e11119.
doi: 10.1097/MD.0000000000011119
27. Mantovani S, Garbelli S, Pasini A, Alimonti D, Perotti C, Melazzini M, et al.
Immune system alterations in sporadic amyotrophic lateral sclerosis patients
suggest an ongoing neuroinflammatory process. J Neuroimmunol. (2009)
210:73–9. doi: 10.1016/j.jneuroim.2009.02.012
28. Brandt LJ, Aroniadis OC, Mellow M, Kanatzar A, Kelly C, Park T, et al. Long-
term follow-up of colonoscopic fecal microbiota transplant for recurrent
Clostridium difficile infection. Am J Gastroenterol. (2012) 107:1079–87.
doi: 10.1038/ajg.2012.60
29. Kelly CR, Ihunnah C, Fischer M, Khoruts A, Surawicz C, Afzali A, et al.
Fecal microbiota transplant for treatment of Clostridium difficile infection
in immunocompromised patients. Am J Gastroenterol. (2014) 109:1065–71.
doi: 10.1038/ajg.2014.133
30. Baxter M, Colville A. Adverse events in faecal microbiota transplant:
a review of the literature. J Hosp Infect. (2016) 92:117–27.
doi: 10.1016/j.jhin.2015.10.024
31. Wang, S, Xu M, Wang W, Cao X, Piao M, Khan S, et al. Systematic
review: adverse events of fecal microbiota transplantation. PLoS ONE.
(2016)11:e0161174. doi: 10.1371/journal.pone.0161174
32. Zhang F, Luo W, Shi Y, Fan Z, Ji G. Should we standardize the 1,700-year-
old fecal microbiota transplantation? Am J Gastroenterol. (2012) 107:1755–6.
doi: 10.1038/ajg.2012.251
33. Brandt LJ. Fecal microbiota transplant: respice, adspice,
prospice. J Clin Gastroenterol. (2015) 49 (Suppl. 1):65–8.
doi: 10.1097/MCG.0000000000000346
34. Eiseman B, Silen W, Bascom GS, Kauvar AJ. Fecal enema as an adjunct in the
treatment of pseudomembranous enterocolitis. Surgery. (1958) 44:854–9.
35. Schwan A, Sjolin S, Trottestam U, Aronsson B. Relapsing clostridium difficile
enterocolitis cured by rectal infusion of homologous faeces. Lancet. (1983)
2:845. doi: 10.1016/S0140-6736(83)90753-5
36. Kassam Z, Lee CH, Yuan Y, Hunt RH. Fecal microbiota transplantation for
Clostridium difficile infection: systematic review and meta-analysis. Am J
Gastroenterol. (2013)108:500–8. doi: 10.1038/ajg.2013.59
37. Cammarota G, Masucci L, Ianiro G, Bibbò S, Dinoi G, Costamagna G, et al.
Randomised clinical trial: faecal microbiota transplantation by colonoscopy
vs. vancomycin for the treatment of recurrent Clostridium difficile infection.
Aliment Pharmacol Ther. (2015) 41:835–43. doi: 10.1111/apt.13144
38. van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM,
et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N
Engl J Med. (2013) 368:407–15. doi: 10.1056/NEJMoa1205037
39. Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC,
Karpinets TV, et al. Gut microbiome modulates response to anti-PD-
1 immunotherapy in melanoma patients. Science. (2018) 359:97–103.
doi: 10.1126/science.aan4236
40. Matson V, Fessler J, Bao R, Chongsuwat T, Zha Y, Alegre M-L, et al. The
commensal microbiome is associated with anti-PD-1 efficacy in metastatic
melanoma patients. Science. (2018) 359:104–8. doi: 10.1126/science.aao3290
41. Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R, et al.
Gut microbiome influences efficacy of PD-1-based immunotherapy against
epithelial tumors. Science. (2018) 359:91–7. doi: 10.1126/science.aan3706
42. Fang X. Potential role of gut microbiota and tissue barriers in Parkinson’s
disease and amyotrophic lateral sclerosis. Int J Neurosci. (2016) 126:771–6.
doi: 10.3109/00207454.2015.1096271
43. Scheperjans F. Can microbiota research change our understanding of
neurodegenerative diseases? Neurodegener Dis Manage. (2016) 6:81–5.
doi: 10.2217/nmt-2015-0012
44. Rowin J, Xia Y, Jung B, Sun J. Gut inflammation and dysbiosis in humanmotor
neuron disease. Physiol Rep. (2017) 5:e13443. doi: 10.14814/phy2.13443
45. Kuraszkiewicz B, Podsiadły-Marczykowska T, Goszczynska H, Piotrkiewicz
M. Are there modifiable environmental factors related to amyotrophic lateral
sclerosis? Front Neurol. (2018) 9:220. doi: 10.3389/fneur.2018.00220
46. Lee YK, Menezes JS, Umesaki Y, Mazmanian SK. Proinflammatory T-
cell responses to gut microbiota promote experimental autoimmune
encephalomyelitis. PNAS. (2011)108:4615–22. doi: 10.1073/pnas.1000082107
47. Tremlett H, Fadrosh DW, Faruqi AA, Hart J, Roalstad S, Graves J, et al. Gut
microbiota composition and relapse risk in pediatric MS: a pilot study. J
Neurol Sci. (2016) 363:153–7. doi: 10.1016/j.jns.2016.02.042
48. Sampson TR, Debelius JW, Thron T, Janssen S, Shastri GG, Ilhan ZE,
et al. Gut microbiota regulate motor deficits and neuroinflammation
in a model of Parkinson’s disease. Cell. (2016)167:1469–80.e12.
doi: 10.1016/j.cell.2016.11.018
49. Scheperjans F, Aho V, Pereira PA, Koskinen K, Paulin L, Pekkonen E, et al.
Gut microbiota are related to Parkinson’s disease and clinical phenotype. Mov
Disord. (2015) 30:350–8. doi: 10.1002/mds.26069
50. Brandscheid C, Schuck F, Reinhardt S, Schäfer KH, Pietrzik CU, Grimm
M, et al. Altered gut microbiome composition and tryptic activity of the
5xFAD Alzheimer’s mouse model. J Alzheimers Dis. (2017) 56:775–88.
doi: 10.3233/JAD-160926
51. Harach T, Marungruang N, Duthilleul N, Cheatham V,Mc Coy KD, Frisoni G,
et al. Reduction of Abeta amyloid pathology in APPPS1 transgenic mice in the
absence of gut microbiota. Sci Rep. (2017) 7:41802. doi: 10.1038/srep46856
52. Borody TJ, Khoruts A. Fecal microbiota transplantation and
emerging applications. Nat Rev Gastroenterol Hepatol. (2011) 9:88–96.
doi: 10.1038/nrgastro.2011.244
53. Kadowaki A, Miyake S, Saga R, Chiba A, Mochizuki H, Yamamura T. Gut
environment-induced intraepithelial autoreactive CD4(+) T cells suppress
central nervous system autoimmunity via LAG-3. Nat Commun. (2016)
7:11639. doi: 10.1038/ncomms11639
54. Round JL, Mazmanian SK. Inducible Foxp3+ regulatory T-cell development
by a commensal bacterium of the intestinal microbiota. PNAS USA. (2010)
107:12204–9. doi: 10.1073/pnas.0909122107
55. Fang X, Wang X, Yang S, Meng F, Wang X, Wei H, et al. Evaluation
of the microbial diversity in amyotrophic lateral sclerosis using high-
throughput sequencing. Front Microbiol. (2016) 7:1479. doi: 10.3389/fmicb.
2016.01479
56. Mazzini L, Mogna L, De Marchi F, Amoruso A, Pane M, Aloisio I, et al.
Potential role of gut microbiota in ALS pathogenesis and possible novel
therapeutic strategies. J Clin Gastroenterol. (2018) 52 (Suppl. 1):S68–70.
doi: 10.1097/MCG.0000000000001042
57. Wu S, Yi J, Zhang YG, Zhou J, Sun J. Leaky intestine and impairedmicrobiome
in an amyotrophic lateral sclerosis mousemodel. Physiol Rep. (2015) 3:e12356.
doi: 10.14814/phy2.12356
58. Zhang YG,Wu S, Yi J, Xia Y, Jin D, Zhou J, et al. Target intestinal microbiota to
alleviate disease progression in amyotrophic lateral sclerosis. Clin Ther. (2017)
39:322–36. doi: 10.1016/j.clinthera.2016.12.014
59. Blacher E, Bashiardes S, Shapiro H, Rothschild D, Mor U, Dori-Bachash M,
et al. Potential roles of gut microbiome and metabolites in modulating ALS in
mice. Nature. (2019) 572:474–80. doi: 10.1038/s41586-019-1443-5
60. Piccione EA, Sletten DM, Staff NP, Low PA. Autonomic system
and amyotrophic lateral sclerosis. Muscle Nerve. (2015) 51:676–9.
doi: 10.1002/mus.24457
61. Furness JB. The enteric nervous system and neurogastroenterology.
Nat Rev Gastroenterol Hepatol. (2012) 9:286–94. doi: 10.1038/nrgastro.
2012.32
62. Quigley EMM. Microbiota-brain-gut axis and neurodegenerative diseases.
Curr Neurol Neurosci Rep. (2017) 17:94. doi: 10.1007/s11910-017-0802-6
63. Pecere S, Sabatelli M, Fantoni M, Ianiro G, Gasbarrini A, Cammarota G.
Letter: faecal microbiota transplantation in combination with fidaxomicin
to treat severe complicated recurrent Clostridium difficile infection. Aliment
Pharmacol Ther. (2015) 42:1030. doi: 10.1111/apt.13362
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2019Mandrioli, Amedei, Cammarota, Niccolai, Zucchi, D’Amico, Ricci,
Quaranta, Spanu and Masucci. This is an open-access article distributed under the
terms of the Creative Commons Attribution License (CC BY). The use, distribution
or reproduction in other forums is permitted, provided the original author(s) and
the copyright owner(s) are credited and that the original publication in this journal
is cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.
Frontiers in Neurology | www.frontiersin.org 12 September 2019 | Volume 10 | Article 1021
